Gilead’s longtime R&D lead Bischofberger steps down

gilead4
(Gilead)

Gilead’s long-serving Norbert Bischofberger, Ph.D., is stepping down as EVP of R&D and chief scientific officer this April, as the company promotes John McHutchison, M.D., to the top job.

McHutchison, currently EVP of clinical research, will become CSO while taking over the company’s R&D org from Bischofberger next month.

This has also caused a domino effect for others at the company. Andrew Cheng, M.D., Ph.D., EVP of clinical research and ops, will become Gilead’s CMO, with both reporting to John Milligan, Ph.D., Gilead’s president and chief.

WEBINAR

Webinar: Meet the Challenge of Complex Protein Expression

As market demand continues to rise for more potent and effective therapeutics, biologic pipelines are evolving from standard antibody formats to next-generation biologics (NGBs). In this webinar we will discuss and demonstrate application through case studies, two significant enhancements to Lonza’s GS Xceed® expression system to help address the challenges of NGBs.

Bischofberger, who started at Gilead in 1990 and became CSO 11 years ago, will leave the company completely in July.

There was no talk of retirement, or why Bischofberger had decided to leave, but Milligan said he and the company “wish him all the best in the next phase of his professional career,” meaning he’s likely to pop up somewhere else soon.

McHutchison has been at Gilead since 2010, coming from Duke University Medical Center, and started out as Gilead’s SVP of liver disease therapeutics. Cheng, meanwhile, has been at the company since 1999, leading its HIV/AIDS programs.

In his new CMO role, Cheng will “retain leadership of the company’s HIV clinical research program and will assume responsibility for Gilead’s medical affairs organization,” as Gilead gears up its HIV/AIDS pipeline, something that has analysts excited for its prospects.

Gilead’s big new prospect, of course, will be its CAR-T program coming out of its $12 billion deal for Kite Pharma last year, and its CAR-T 2.0 attempts with its much cheaper buyout of Cell Design Labs in December.

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.